## Abstract Sera from 20 Chinese patients with chronic hepatitis B were examined for hepatitis B e antigen and hepatitis B virus (HBV) DNA. There was considerable discordance with HBV DNA not being detectable in 10 out of 13 (77%) patients who were hepatitis B e antigen positive. Further testing fo
Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to the hepatitis B core antigen
✍ Scribed by Kang-Xian Luo; Rong Zhou; Chao He; Zhi-Sen Liang; Dr. Shibo Jiang
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 500 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The prevalence of serum HBV DNA in individuals positive for anti‐HBc alone was determined by the polymerase chain reaction in two groups with endemic HBV infection from Canton (group A) and Hainan (group B), provinces of China. Twenty‐one out of 294 individuals in group A (7.2%) and 193 out of 1995 in group B (9.7%) were positive for anti‐HBc but negative for other markers of ongoing or past HBV infection. (HBsAg and anti‐HBs). HBV DNA was detected in 6/21 sera in group A (28.6%) and 68/193 in group B (35.2%) in their initial serum specimen. One of the six HBV‐DNA‐positive individuals in group A became negative after 6 months and four of the 58 positive in group B became negative at 4 years of follow‐up. All of the individuals remained positive for anti‐HBc and negative for anti‐HBs, but one of them became positive for HBsAg on follow‐up. None of the anti‐HBc‐ and HBV‐DNA‐positive subjects had symptoms of liver diseases. They were, therefore, defined as chronic asymptomatic HBV carriers with undetectable HBsAg. This type of carrier should be added to the typical HBsAg‐positive carrier, who constitutes about 10–15% of the general Chinese population, to give a more complete estimate of asymptomatic HBV carriers in China.
📜 SIMILAR VOLUMES
A variety of prophylactic strategies are used to prevent the risk of hepatitis B virus (HBV) transmission from antibody to hepatitis B core antigen (anti-HBc)-positive donors. The mechanisms underlying the failure of HBV immunoglobulin monoprophylaxis have been poorly evaluated. Seventy-seven anti-H
Little is known about the immunoglobulin class of antibodies to HBcAg. In the present study sera containing anti-HBc were fractionated by surcose density-gradient centrifugation, and all serum fractions were tested against HBcAg by immunoelectro-osmophoresis. In addition selected fractions were exam
This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ؍ 60